DNAPrint announces German business partner's progress in European clinical trial for BF-200.

(From Chemical Business NewsBase - Press Release)

DNAPrint Genomics Inc announced that its German business partner, Biofrontera AG, has completed the enrollment of patients in the first part of its Phase IIb/III clinical trial for its lead product, BF-200 ALA, a proposed treatment of actinic keratosis. Initially, clinical results for three different doses of the active ingredient 5-aminolevulinic acid (ALA) and placebo are compared. Following the treatment and 2-month observation of 80 patients enrolled in the first part of the study, independent experts will perform an interim analysis to select the optimal dose of the drug. All 80 patients have already completed …